当前位置: 首页 >> 检索结果
301. Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure and Preserved Ejection Fraction.
作者: Maura M Zylla.;Johannes Leiner.;Ann-Kathrin Rahm.;Tobias Hoffmann.;Patrick Lugenbiel.;Patrick Schweizer.;Eberhard Scholz.;Derliz Mereles.;Dorothea Kronsteiner.;Meinhard Kieser.;Hugo A Katus.;Norbert Frey.;Dierk Thomas.
来源: Circ Heart Fail. 2022年15卷9期e009281页
Coexistence of atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) is common, affecting morbidity and prognosis. This study evaluates outcome after cryoballoon ablation for AF in HFpEF compared with patients without heart failure.
302. Edge-to-Edge Transcatheter Mitral Valve Repair Versus Optimal Medical Treatment in Nonresponders to Cardiac Resynchronization Therapy: The MITRA-CRT Trial.
作者: Xavier Freixa.;Jose María Tolosana.;Pedro L Cepas-Guillen.;Marco Hernández-Enríquez.;Laura Sanchis.;Eduardo Flores-Umanzor.;Marta Farrero.;Rut Andrea.;Mercè Roqué.;Maria José Carretero.;Ander Regueiro.;Salvatore Brugaletta.;Josep Rodés-Cabau.;Lluís Mont.;Marta Sitges.;Manel Sabaté.;M Ángeles Castel.
来源: Circ Heart Fail. 2022年15卷12期e009501页 303. Prognostic Value of Measuring Fractional Flow Reserve After Percutaneous Coronary Intervention in Patients With Complex Coronary Artery Disease: Insights From the FAME 3 Trial.
作者: Zsolt Piroth.;Hisao Otsuki.;Frederik M Zimmermann.;Tamás Ferenci.;Danielle C J Keulards.;Alan C Yeung.;Nico H J Pijls.;Bernard De Bruyne.;William F Fearon.
来源: Circ Cardiovasc Interv. 2022年15卷11期884-891页
We evaluate the prognostic value of measuring fractional flow reserve (FFR) after percutaneous coronary intervention (post-PCI FFR) and intravascular imaging in patients undergoing PCI for 3-vessel coronary artery disease in the FAME 3 trial (Fractional Flow Reserve versus Angiography for Multivessel Evaluation).
304. Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-Up Outcomes of Multicenter Randomized Controlled BEST Trial.
作者: Jung-Min Ahn.;Do-Yoon Kang.;Sung-Cheol Yun.;Seung Ho Hur.;Hun-Jun Park.;Damras Tresukosol.;Woong Chol Kang.;Hyuck Moon Kwon.;Seung-Woon Rha.;Do-Sun Lim.;Myung-Ho Jeong.;Bong-Ki Lee.;He Huang.;Young Hyo Lim.;Jang Ho Bae.;Byung Ok Kim.;Tiong Kiam Ong.;Sung Gyun Ahn.;Cheol-Hyun Chung.;Duk-Woo Park.;Seung-Jung Park.; .
来源: Circulation. 2022年146卷21期1581-1590页
Long-term comparative outcomes after percutaneous coronary intervention (PCI) with everolimus-eluting stents and coronary artery bypass grafting (CABG) are limited in patients with multivessel coronary artery disease.
305. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
作者: Javed Butler.;Gerasimos Filippatos.;Tariq Jamal Siddiqi.;João Pedro Ferreira.;Martina Brueckmann.;Edimar Bocchi.;Michael Böhm.;Vijay K Chopra.;Nadia Giannetti.;Tomoko Iwata.;James L Januzzi.;Sanjay Kaul.;Ileana L Piña.;Piotr Ponikowski.;Ursula Rauch-Kröhnert.;Sanjiv J Shah.;Michele Senni.;Mikhail Sumin.;Subodh Verma.;Jian Zhang.;Stuart J Pocock.;Faiez Zannad.;Milton Packer.;Stefan D Anker.
来源: Circulation. 2022年146卷14期1046-1055页
Women and men with heart failure (HF) and preserved ejection fraction may differ in their clinical characteristics and their response to therapy. The aim of this study was to evaluate the influence of sex on the effects of empagliflozin in patients with HF and preserved ejection fraction enrolled in the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction).
306. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
作者: Amil M Shah.;Brian Claggett.;Narayana Prasad.;Guichu Li.;Mayra Volquez.;Karola Jering.;Maja Cikes.;Attila Kovacs.;Wilfried Mullens.;Jose C Nicolau.;Lars Køber.;Peter van der Meer.;Pardeep S Jhund.;Ghionul Ibram.;Martin Lefkowitz.;Yinong Zhou.;Scott D Solomon.;Marc A Pfeffer.
来源: Circulation. 2022年146卷14期1067-1081页
Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV) enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits with combined angiotensin receptor neprilysin inhibition, but human data are conflicting. The PARADISE-MI Echo Study (Prospective ARNI Versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction) tested the effect of sacubitril/valsartan compared with ramipril on LV function and adverse remodeling after high risk-AMI.
307. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study.
作者: Jonas Oldgren.;Signild Åsberg.;Ziad Hijazi.;Per Wester.;Maria Bertilsson.;Bo Norrving.; .
来源: Circulation. 2022年146卷14期1056-1066页
There are no evidence-based recommendations on the optimal time point to initiate non-vitamin K antagonist oral anticoagulants (NOACs) after acute ischemic stroke in patients with atrial fibrillation. We aimed to investigate the efficacy and safety of early versus delayed initiation of NOAC in these patients.
308. Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B.
作者: Marc P Bonaca.;David A Morrow.;Brian A Bergmark.;David D Berg.;Joao A C Lima.;Udo Hoffmann.;Yoko Kato.;Michael T Lu.;Julia Kuder.;Sabina A Murphy.;Jindrich Spinar.;Ton Oude Ophuis.;Róbert G Kiss.;Jose Lopez-Sendon.;Oleg Averkov.;Stephen B Wheatcroft.;Jacek Kubica.;Jose Carlos Nicolau.;Remo H M Furtado.;Liron Abuhatzira.;Boaz Hirshberg.;Sami A Omar.;Andrea L Vavere.;Yi-Ting Chang.;Richard T George.;Marc S Sabatine.
来源: Circulation. 2022年146卷12期907-916页
High-density lipoprotein plays a key role in reverse cholesterol transport. In addition, high-density lipoprotein particles may be cardioprotective and reduce infarct size in the setting of myocardial injury. Lecithin-cholesterol acyltransferase is a rate-limiting enzyme in reverse cholesterol transport. MEDI6012 is a recombinant human lecithin-cholesterol acyltransferase that increases high-density lipoprotein cholesterol. Administration of lecithin-cholesterol acyltransferase has the potential to reduce infarct size and regress coronary plaque in acute ST-segment-elevation myocardial infarction.
309. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT.
作者: Erin A Bohula.;David D Berg.;Mathew S Lopes.;Jean M Connors.;Ijlal Babar.;Christopher F Barnett.;Sunit-Preet Chaudhry.;Amit Chopra.;Wilson Ginete.;Michael H Ieong.;Jason N Katz.;Edy Y Kim.;Julia F Kuder.;Emilio Mazza.;Dalton McLean.;Jarrod M Mosier.;Ari Moskowitz.;Sabina A Murphy.;Michelle L O'Donoghue.;Jeong-Gun Park.;Rajnish Prasad.;Christian T Ruff.;Mohamad N Shahrour.;Shashank S Sinha.;Stephen D Wiviott.;Sean Van Diepen.;Mark Zainea.;Vivian Baird-Zars.;Marc S Sabatine.;David A Morrow.; .
来源: Circulation. 2022年146卷18期1344-1356页
The efficacy and safety of prophylactic full-dose anticoagulation and antiplatelet therapy in critically ill COVID-19 patients remain uncertain.
310. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
作者: Michelle L O'Donoghue.;Robert P Giugliano.;Stephen D Wiviott.;Dan Atar.;Anthony Keech.;Julia F Kuder.;KyungAh Im.;Sabina A Murphy.;Jose H Flores-Arredondo.;J Antonio G López.;Mary Elliott-Davey.;Bei Wang.;Maria Laura Monsalvo.;Siddique Abbasi.;Marc S Sabatine.
来源: Circulation. 2022年146卷15期1109-1119页
In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and risk of cardiovascular events and was safe and well tolerated over a median of 2.2 years of follow-up. However, large-scale, long-term data are lacking.
311. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
作者: Sunil V Rao.;Bodo Kirsch.;Deepak L Bhatt.;Andrzej Budaj.;Rosa Coppolecchia.;John Eikelboom.;Stefan K James.;W Schuyler Jones.;Bela Merkely.;Lars Keller.;Renicus S Hermanides.;Gianluca Campo.;José Luis Ferreiro.;Taro Shibasaki.;Hardi Mundl.;John H Alexander.; .
来源: Circulation. 2022年146卷16期1196-1206页
Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI).
312. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
作者: Alexander Peikert.;Felipe A Martinez.;Muthiah Vaduganathan.;Brian L Claggett.;Ian J Kulac.;Akshay S Desai.;Pardeep S Jhund.;Rudolf A de Boer.;David DeMets.;Adrian F Hernandez.;Silvio E Inzucchi.;Mikhail N Kosiborod.;Carolyn S P Lam.;Sanjiv J Shah.;Tsvetana Katova.;Béla Merkely.;Orly Vardeny.;Ulrica Wilderäng.;Daniel Lindholm.;Magnus Petersson.;Anna Maria Langkilde.;John J V McMurray.;Scott D Solomon.
来源: Circ Heart Fail. 2022年15卷10期e010080页
The prevalence of heart failure with mildly reduced or preserved ejection fraction markedly increases with age, with older individuals disproportionately facing excess risk for mortality and hospitalization.
313. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.
作者: Jawad H Butt.;Pardeep S Jhund.;Jan Belohlávek.;Rudolf A de Boer.;Chern-En Chiang.;Akshai S Desai.;Jarosław Drożdż.;Adrian F Hernandez.;Silvio E Inzucchi.;Tzvetana Katova.;Masafumi Kitakaze.;Mikhail N Kosiborod.;Carolyn S P Lam.;Anna Maria Langkilde.;Daniel Lindholm.;Erasmus Bachus.;Felipe Martinez.;Béla Merkely.;Magnus Petersson.;Jose F Kerr Saraiva.;Sanjiv J Shah.;Muthiah Vaduganathan.;Orly Vardeny.;Ulrica Wilderäng.;Brian L Claggett.;Scott D Solomon.;John J V McMurray.
来源: Circulation. 2022年146卷16期1210-1224页
Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be less likely to receive new pharmacologic treatments. We investigated the efficacy and tolerability of dapagliflozin according to frailty status in patients with heart failure with mildly reduced or preserved ejection fraction randomized in DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure).
314. Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
作者: Francesco Cosentino.;Christopher P Cannon.;Robert Frederich.;David Z I Cherney.;Samuel Dagogo-Jack.;Richard E Pratley.;James P Mancuso.;Mario Maldonado.;Nilo B Cater.;Shuai Wang.;Darren K McGuire.
来源: Circulation. 2022年146卷8期652-654页 315. Sequential Interventions for Major Depression and Heart Failure Self-Care: A Randomized Clinical Trial.
作者: Kenneth E Freedland.;Judith A Skala.;Robert M Carney.;Brian C Steinmeyer.;Eugene H Rubin.;Michael W Rich.
来源: Circ Heart Fail. 2022年15卷8期e009422页
Major depression and inadequate self-care are common in patients with heart failure (HF). Little is known about how to intervene when both problems are present. This study examined the efficacy of a sequential approach to treating these problems.
316. Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial.
作者: Bernard R Chaitman.;Derek D Cyr.;Karen P Alexander.;Radosław Pracoń.;Kevin R Bainey.;Anoop Mathew.;Anjali Acharya.;Dennis F Kunichoff.;Jerome L Fleg.;Renato D Lopes.;Mandeep S Sidhu.;Rebecca Anthopolos.;Frank W Rockhold.;Gregg W Stone.;David J Maron.;Judith S Hochman.;Sripal Bangalore.
来源: Circ Cardiovasc Interv. 2022年15卷8期e012103页
ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) reported an initial invasive treatment strategy did not reduce the risk of death or nonfatal myocardial infarction (MI) compared with a conservative treatment strategy in patients with advanced chronic kidney disease, stable coronary disease, and moderate or severe myocardial ischemia. The cumulative frequency of different MI type after randomization and subsequent prognosis have not been reported.
317. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
作者: Kieran F Docherty.;Paul Welsh.;Subodh Verma.;Rudolf A De Boer.;Eileen O'Meara.;Olof Bengtsson.;Lars Køber.;Mikhail N Kosiborod.;Ann Hammarstedt.;Anna Maria Langkilde.;Daniel Lindholm.;Dustin J Little.;Mikaela Sjöstrand.;Felipe A Martinez.;Piotr Ponikowski.;Marc S Sabatine.;David A Morrow.;Morten Schou.;Scott D Solomon.;Naveed Sattar.;Pardeep S Jhund.;John J V McMurray.; .
来源: Circulation. 2022年146卷13期980-994页
Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We also analyzed the effect of dapagliflozin on outcomes, according to iron status at baseline.
318. Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden.
作者: Andreas Rillig.;Katrin Borof.;Günter Breithardt.;A John Camm.;Harry J G M Crijns.;Andreas Goette.;Karl-Heinz Kuck.;Andreas Metzner.;Panos Vardas.;Eik Vettorazzi.;Karl Wegscheider.;Antonia Zapf.;Paulus Kirchhof.
来源: Circulation. 2022年146卷11期836-847页
The randomized EAST-AFNET4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial-Atrial Fibrillation Network) demonstrated that early rhythm control (ERC) reduces adverse cardiovascular outcomes in patients with recently diagnosed atrial fibrillation and stroke risk factors. The effectiveness and safety of ERC in patients with multiple cardiovascular comorbidities is not known.
319. Routine Pressure Wire Assessment Versus Conventional Angiography in the Management of Patients With Coronary Artery Disease: The RIPCORD 2 Trial.
作者: Rodney H Stables.;Liam J Mullen.;Mostafa Elguindy.;Zoe Nicholas.;Yousra H Aboul-Enien.;Ian Kemp.;Peter O'Kane.;Alex Hobson.;Thomas W Johnson.;Sohail Q Khan.;Stephen B Wheatcroft.;Scot Garg.;Azfar G Zaman.;Mamas A Mamas.;James Nolan.;Sachin Jadhav.;Colin Berry.;Stuart Watkins.;David Hildick-Smith.;Julian Gunn.;Dwayne Conway.;Angels Hoye.;Iftikhar A Fazal.;Colm G Hanratty.;Bernard De Bruyne.;Nick Curzen.
来源: Circulation. 2022年146卷9期687-698页
Measurement of fractional flow reserve (FFR) has an established role in guiding percutaneous coronary intervention. We tested the hypothesis that, at the stage of diagnostic invasive coronary angiography, systematic FFR-guided assessment of coronary artery disease would be superior, in terms of resource use and quality of life, to assessment by angiography alone.
320. Efficacy of Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure According to Sex: Extended Follow-Up Study of the DANISH Trial.
作者: Jawad H Butt.;Adelina Yafasova.;Marie B Elming.;Ulrik Dixen.;Jens C Nielsen.;Jens Haarbo.;Lars Videbæk.;Eva Korup.;Niels E Bruun.;Hans Eiskjær.;Axel Brandes.;Anna M Thøgersen.;Finn Gustafsson.;Kenneth Egstrup.;Christian Hassager.;Jesper Hastrup Svendsen.;Dan E Høfsten.;Christian Torp-Pedersen.;Steen Pehrson.;Jens Jakob Thune.;Lars Køber.
来源: Circ Heart Fail. 2022年15卷9期e009669页
Men and women may respond differently to certain therapies for heart failure with reduced ejection fraction, including implantable cardioverter defibrillators (ICD). In an extended follow-up study of the DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heart Failure on Mortality), adding 4 years of additional follow-up, we examined the effect of ICD implantation according to sex.
|